Physician profile
Carl Howard June
NPI 1386687689
$9,018,433.28
in general payments reported to CMS, 2019-2025
13 companies · $9.0M in 2025
The $9.0M reported for 2025 was more than what 99% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $3,236 · 2021: $4,896 · 2023: $7,851 · 2024: $12K · 2025: $9.0M.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $9.0M · Consulting Fee: $27K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,539 · Travel and Lodging: $2,119 · Food and Beverage: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $8,978,680.46 |
| Consulting Fee | $26,760.80 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,539.14 |
| Travel and Lodging | $2,118.90 |
| Food and Beverage | $202.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,978,680.46 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $13,600.36 | 2023-2025 | |
| Gilead Sciences, INC. | $8,249.63 | 2024-2025 | Yescarta |
| Janssen Scientific Affairs, LLC | $4,050.00 | 2024 | Imbruvica |
| Sanofi US Services INC. | $3,235.50 | 2020 | |
| Amgen INC. | $2,596.00 | 2021 | |
| Celgene Corporation | $2,539.14 | 2024 | |
| Glaxosmithkline, LLC. | $2,300.00 | 2021 | |
| Astrazeneca Uk Limited | $1,825.00 | 2025 | |
| Merck Sharp & Dohme LLC | $1,238.38 | 2024 | |
| Mckesson Sourcing Services, INC. | $60.37 | 2023 | |
| Kite Pharma, INC. | $58.44 | 2023-2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl June listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.